MTOR and posterior cortical atrophy: Stelloo et al. showed that PCa patients with a high risk of relapse have low-mTOR-expressing tumors with an inactive mTOR pathway [17], and similarly, Muller et al. demonstrated that the loss of p-mTOR staining was significantly linked to early biochemical recurrence across various types of cancers [26].